The cythochrome P450 gene produts are responsible for metabolizing a large number of widely prescribed drugs. Clopidogrel (Plavix(R)) is metabolized by cytochrome P450 2C19 (CYP2C19, S-mephenytoin 4-prime-hydroxylase) to its active form. Poor metabolizers (PM) will require increased dosage to obtain therapeutic levels, while ultra-extensive metoblizers (UM) will require a decreased dosage due to higher than normal rates of drug metabolism. CYP2C19 catalyzes the hydroxylation of a number of clinically important drugs, including omeprazole, proguanil, hexobarbital, imipramine and to a lesser extent, propranolol and diazepam. CYP2C19 loss-of-function alleles were shown to be associated with a higher rate of subsequent cardiovascular events among patients with an acute myocardial infarction and were receiving clopidogrel treatment (N Engl J Med. 2009;360:363-375).
Whole blood: Normal phlebotomy procedure. Specimen stability is
crucial. Store and ship immediately. Saliva collection kits require
patient to rinse mouth prior to spitting into Oragene collection kit.
See Oragene product insert for further details.
Reported (Analytical Time)
The CPT codes provided are based on AMA guidelines and are for informational purposes only.
CPT coding is the sole responsibility of the billing party.
Please direct any questions regarding coding to the payer being billed.
**For non-New York patient testing, use test code 16924 - AccuType(R) CP, Clopidogrel CYP2C19 Genotype.**
Transport Temperature: Room temperature
Methodology: Polymerase Chain Reaction/Single Nucleotide Primer Extension